Medexus Pharmaceuticals reports Q2 results
- Medexus Pharmaceuticals press release (MEDXF): Q2 Revenue of $29.1M (+17.8% Y/Y) misses by $1.31M.
Adjusted EBITDA of $5.1M, operating income of $2.4M, and net income of $0.8M - all quarterly records since fiscal Q4 2025, demonstrating significant year-over-year growth.
Product-level net revenue from GRAFAPEX™ (treosulfan) for Injection of $5.7M also a quarterly record.
Medexus continues to expect to achieve annual product-level net revenue from GRAFAPEX of approximately $100M to $175M within five years after commercial launch.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.